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Summary objective To identify risk factors for in-hospital mortality in patients treated for visceral leishmaniasis
(VL) in Uganda.
methods Retrospective analysis of VL patients’ clinical data collected for project monitoring by
Me ´decins Sans Frontie `res in Amudat, eastern Uganda.
results Between 2000 and 2005, of 3483 clinically suspect patients, 53% were conﬁrmed with pri-
mary VL. Sixty-two per cent were children <16 years of age with a male⁄female ratio of 2.2. The overall
case-fatality rate during pentavalent antimonial (n = 1641) or conventional amphotericin B treatment
(n = 217) was 3.7%. There was no difference in the case-fatality rate between treatment groups
(P > 0.20). The main risk factors for in-hospital death identiﬁed by a multivariate analysis were age
<6 years and >15 years, concomitant tuberculosis or hepatopathy, and drug-related adverse events. The
case-fatality rate among patients >45 years of age was strikingly high (29.0%).
conclusion Subgroups of VL patients at higher risk of death during treatment with drugs currently
available in Uganda were identiﬁed. Less toxic drugs should be evaluated and used in these patients.
keywords visceral leishmaniasis, pentavalent antimonials, amphotericin B, death rate, Uganda,
retrospective analysis
Introduction
Visceral leishmaniasis (VL), a protozoal disease, is esti-
mated to affect 500 000 persons every year worldwide
(Desjeux 2004). In East Africa, VL is caused by a
Leishmania species belonging to the Leishmania donovani
complex (Jamjoom et al. 2004). The main endemic focus
in Africa is Sudan, but the disease is also endemic in
remote regions of Somalia, Ethiopia, Kenya and Uganda.
VL is not part of the routine national data collection
systems, which contributes to the lack of epidemiological
and clinical data (Guerin et al. 2002).
Several drugs can be used for the treatment of VL, with
different efﬁcacy and safety proﬁles. Both parasite and host
determinants can inﬂuence the rate of treatment failure
(Croft et al. 2006). In East Africa, pentavalent antimonials
(SbV) and amphotericin B (ampB) deoxycholate are used as
ﬁrst- and second-line treatments, respectively. In contrast
to the situation in the Indian subcontinent (Olliaro et al.
2005), SbV drugs remain overall effective in East African
countries. Branded (Pentostam ; Glaxo Smith Kline, UK)
and generic (SAG; Albert David, India) sodium stibogluc-
onate (SSG) and meglumine antimoniate (Glucantime ;
Sanoﬁ-aventis, France) are the three commercialized SbV
drugs recommended by WHO (WHO 1996). Generic SSG
is as safe and effective as Pentostam  for the treatment of
VL in Kenya, Ethiopia and Sudan (Veeken et al. 2000;
Moore et al. 2001; Ritmeijer et al. 2001).
Adverse effects are frequent with SbV and death because
of acute pancreatitis or cardiac disrhythmia may occur.
The case-fatality rate in VL patients treated with SbV has
been reported to be as high as 18.5% (Lyons et al. 2003).
Death can be due to direct drug toxicity or VL itself in
patients with advanced disease, as SbV drugs are rather
slow-acting. Mortality is particularly high among HIV
patients. A study undertaken in southern Sudan, analysing
a cohort of 1207 adults treated with SSG, identiﬁed long
duration of illness (>5 months), age >45 years, severe
anaemia [haemoglobin (Hb) count <6 g⁄dl], severe mal-
nutrition (Body Mass Index, BMI <14 kg⁄m
2) and vomit-
ing as risk factors for death (Seaman et al. 1996). Another
study conducted in the same setting analysed 3365 patients
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malnutrition (BMI <13 kg⁄m
2), anaemia (Hb <8 g⁄dl) and
duration of illness (‡5 months) were risk factors for death
in adults, whereas age <2 years, malnutrition (weight-for-
height <60%), anaemia (Hb <6 g⁄dl), and splenomegaly
were identiﬁed as risk factors in children and adolescents.
Diarrhoea, vomiting, and bleeding were also associated
with a higher risk of death in Sudan and in Ethiopia (Lyons
et al. 2003; Collin et al. 2004). Concomitant HIV infection
was the strongest predictor of death [odds ratio (OR) = 4.5,
95% conﬁdence interval (CI): 1.8–11.4] in the Ethiopian
study (Lyons et al. 2003). High rates of severe adverse
effects and death among HIV–VL co-infected patients
treated with SbV have also been reported in Europe
(Delgado et al. 1999).
Amphotericin B deoxycholate is generally used to treat
patients with SbV failures in East Africa. This drug
frequently causes infusion-related adverse effects such as
fever and chills. Severe adverse effects such as anaphylactic
reactions, renal insufﬁciency or hypokalemia may occur.
Whereas ampB deoxycholate was found to be effective and
relatively safe in Indian rural hospitals (Thakur & Ahmed
2001), it did not perform better than SbV in Uganda
(Mueller et al. 2008). Amphotericin B also exists in various
lipid formulations, of which liposomal ampB (Ambisome ;
Gilead Pharma, Foster City, CA, USA) has been the most
extensively validated (Sundar et al. 2004; Bern et al. 2006).
Liposomal ampB, which is better tolerated than ampB
deoxycholate, is highly effective and safe in India and
showed promising results in East Africa (Olliaro et al.
2005; Bern et al. 2006). Miltefosine and paromomycin,
which have been recently evaluated and registered in India,
are being studied in East Africa (Ritmeijer et al. 2006).
As several anti-leishmanial drugs are (or will be soon)
available in East Africa, it is crucial to identify the
subgroups of VL patients at increased risk of death with
the currently used treatment. They might beneﬁt from a
different ﬁrst-line therapy. We retrospectively analysed the
clinical data on VL patients collected during a VL project
conducted by Me ´decins Sans Frontie `res (MSF) in Amudat
Hospital, eastern Uganda, to identify the risk factors for
death during treatment.
Patients and methods
From January 2000 to December 2005, data were collected
at Amudat Hospital, a 120-bed rural hospital located in
Pokot County, Nakapiripirit District, Uganda. Pokot
County is part of a larger VL endemic focus that also
includes the Pokot North, West Pokot, East Pokot and
Baringo districts in Kenya. The main objective of the MSF
project in Pokot County was to support medical activities
at Amudat Hospital, including the diagnosis and treatment
of VL. All patients who were clinically suspect (fever for
>14 days with splenomegaly or wasting) were further
investigated for VL. The diagnosis algorithm is described
elsewhere (Chappuis et al. 2005). In brief, diagnostic
conﬁrmation was obtained by serology or parasitology
(spleen or lymph node aspirate). Serological methods were
the direct agglutination test (DAT) from 2000 to 2004 or
the rk39 antigen based DiaMed IT-Leish (DiaMed AG,
Cressier sur Morat, Switzerland) dipstick test after its local
validation in 2004 (Chappuis et al. 2005). Testing for HIV
was not performed routinely because of the absence of
voluntary counselling and testing facilities and the lack of
available antiretroviral treatment in the district.
First-line treatment of primary VL was intramuscular
meglumine antimoniate (Glucantime )2 0m g
SbV⁄kg⁄day for 30 days, without upper dose limit. Sec-
ond-line treatment was intravenous ampB deoxycholate 1
mg⁄kg on alternate days for 30 days (15 doses). AmpB
deoxycholate had to be introduced as ﬁrst-line treatment
during a 9-month shortage of Glucantime  (August 2003–
April 2004) (Mueller et al. 2008). Sodium stibogluconate
(Pentostam ) was then used as the ﬁrst-line treatment
from May 2004 until December 2005.
Demographic and medical data of all VL patients were
entered in a Microsoft Excel spreadsheet. Only patients
with conﬁrmed VL and no history of previous anti-
leishmanial treatment (primary VL) were retained for the
analysis of risk factors for mortality. Statistical analysis
was performed using the Stata 9  software (Stata Corpo-
ration, College Station, TX, USA). First, a univariate
analysis was performed exploring the association between
the explanatory variables and the outcome (in-hospital
mortality). Continuous variables were recoded into pre-
deﬁned categories to allow for comparison with previous
studies (e.g. age, anaemia) or were categorized by centiles
(e.g. spleen size, weight, height, weeks of illness). Crude
odds ratio and its 95% CI were calculated. Variables
showing non-normal distribution and discrete variables
were analysed with the Kruskal–Wallis rank test. Catego-
rization of nutritional status was based on percentage of
the median weight-for-height (% W⁄H) for children under
137 cm (females) or 145 cm (males) (%W⁄H <70: severe
malnutrition, %W⁄H 70 to 79: moderate malnutrition,
%W⁄H 80 to 89: mild malnutrition, %W⁄H ‡90: no
malnutrition), and on BMI for adults (BMI £16: severe
malnutrition, BMI 16–17: moderate malnutrition, BMI
17–18: mild malnutrition, >18 kg: no malnutrition). For
the analysis of risk factors for mortality, additional cut-offs
were used in order to ensure comparability with previous
studies (Seaman et al. 1996; Collin et al. 2004). Malnu-
trition assessed by the BMI and the weight⁄height ratio
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Variables associated with the outcome in the univariate
analysis at a level of signiﬁcance of P £ 0.20 were included
in the multivariate analysis. The multivariate analysis was
performed using a logistic regression model in a stepwise
forward procedure. Results are presented with 95%
conﬁdence intervals where appropriate.
Results
Between 2000 and 2005, 3483 suspected VL patients were
admitted to Amudat Hospital. Fifty-ﬁve per cent (1904)
were then conﬁrmed as VL patients. Among the non-VL
cases, the most frequent diagnoses were hyperreactive
malarial splenomegaly (HMS; previously known as tropical
splenomegaly syndrome) and smear-proven malaria or
brucellosis. Forty-six VL patients had a previous history of
anti-leishmanialtreatmentandwereexcludedfromanalysis.
Of the remaining 1858 patients, 68 died during hospital-
ization, resulting in a case-fatality rate of 3.7%. The
diagnosis of VL was conﬁrmed by DAT (titre >1:12 800) in
1176 patients (63%), by DiaMed IT-Leish in 499 patients
(27%),byparasitologicaldiagnosisofspleenaspiratein178
patients (10%), and of lymph node aspirate in ﬁve patients.
Univariate analysis
The majority of the patients were children aged <16 years
(62.8%), with a male:female sex ratio of 2.2. Mortality
was lowest in the age category 6–15 years (Table 1),
whereas age <6 years and >15 years were risk factors for
higher mortality. In particular, age >45 years was a strong
risk factor for death (OR = 33.05, 95% CI: 11.40–95.80).
Other factors associated with mortality were female sex,
residence 51–100 km from Amudat (compared with
<15 km), and duration of illness >10 weeks (compared
with <6 weeks). Only 20% patients were not malnourished
(BMI >18 kg⁄m
2 or W⁄H ‡90%). Malnutrition, measured
by either BMI or W⁄H was not a risk factor for death
(P > 0.20 for all categories; Table 2). Severely enlarged
spleen of more than 14 cm below the costal margin was a
risk factor for death compared with spleen enlargement of
less than 11 cm. Ninety-six per cent of patients presented
with anaemia, which was not associated with increased
mortality. Mild anaemia was negatively associated with
mortality (P = 0.004).
Forty-ﬁve per cent of patients presented one or more
concomitant infection(s) such as acute respiratory infec-
tions (32%), malaria (21%), ear, nose or throat infections
Table 1 Risk factors for in-hospital death among 1858 primary VL cases at Amudat hospital, Uganda: univariate analysis of demographic
characteristics
Total (n = 1858) Deaths (n = 68) CFR
P-value OR 95% CI of OR n % n %
Age
0–5 years 335 18.3 14 4.2 0.001 3.52 1.54, 8.05
6–15 years 818 44.6 10 1.2 1
16–45 years 650 35.4 31 4.8 <0.001 4.05 1.96, 8.35
Over 45 years 31 1.7 9 29.0 <0.001 33.05 11.40, 95.80
Sex
Male 1283 69.0 39 3.0 1
Female 575 31.0 29 5.0 0.033 1.69 1.04, 2.77
Country of origin
Uganda 565 30.5 15 2.6 1
Kenya 1290 69.5 53 4.1 0.125 1.57 0.88, 2.81
Distance from Amudat
0–15 km 345 19.4 7 2.0 1
16–50 km 782 44.0 28 3.6 0.167 1.79 0.77, 4.15
51–100 km 492 27.7 26 5.3 0.017 2.69 1.15, 6.30
>100 km 157 8.8 3 1.9 >0.20 0.94 0.24, 3.69
Duration of illness
0–5 weeks 579 31.4 14 2.4 1
6–10 weeks 650 35.2 19 2.9 >0.20 1.21 0.60, 2.45
>10 weeks 617 33.4 33 5.3 0.009 2.28 1.20, 4.31
P-value based on chi-square tests.
CFR, case-fatality rate.
Missing values: 24 for variable age, 0 for sex, 3 for origin, 82 for distance, and 12 for duration of illness.
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culosis, liver disease (deﬁned by clinical jaundice and⁄or by
a positive hepatitis B surface antigen) and diarrhoea were
associated with fatal outcome. Pregnancy was also strongly
associated with death; 861 (46%) patients were treated
with Pentostam , 666 (36%) with Glucantime , 217
(12%) with ampB deoxycholate, and 109 (6%) with
Glucantime  completed by Pentostam . Five patients
died in the hospital before treatment was started. There
was no difference in case-fatality rates between the
different treatments used (3.7% for Pentostam, 2.8% for
Glucantime, 1.8% for a combination of both, and 4.6%
for ampB; P > 0.20). Adverse events, reported in 7% of the
cases (n = 134), were associated with higher mortality.
Multivariate analysis
All 13 variables associated with death in the univariate
analysis were included in the multivariate logistic regres-
sion model. After adjusting for the other variables in the
model, home location 51–100 km from Amudat, duration
of illness >10 weeks and diarrhoea were not found to be
signiﬁcantly associated with increased mortality, and were
therefore excluded from the model. The association
Table 2 Risk factors for in-hospital death among 1858 primary VL cases at Amudat hospital, Uganda: univariate analysis of clinical
characteristics
Total
(n = 1858) Deaths (n = 68) CFR
P-value OR 95% CI of OR n % n %
Nutritional status
BMI (n = 775)
>18.0 155 20.0 9 5.8 1
17.1–18.0 150 19.3 10 6.7 >0.20 1.16 0.46, 2.94
16.1–17.0 171 22.1 11 6.4 >0.20 1.11 0.45, 2.77
15.1–16.0 150 19.3 5 3.3 >0.20 0.56 0.18, 1.72
14.1–15.0 82 10.6 4 4.9 >0.20 0.83 0.25, 2.80
13.1–14.0 44 5.7 3 6.8 >0.20 1.19 0.31, 4.60
£13.0 23 3.0 0 0.0 >0.20 0.00 –
W⁄H( n = 1024)
‡90 210 20.5 5 2.4 1
80–89 490 47.8 10 2.0 >0.20 0.85 0.29, 2.53
70–79 268 26.2 8 3.0 >0.20 1.26 0.41, 3.92
<70 56 5.5 2 3.6 >0.20 1.52 0.29, 8.07
Spleen size on admission
<11 cm 587 31.9 14 2.4 1
11–14 cm 599 32.5 17 2.8 >0.20 1.20 0.58, 2.45
>14 cm 654 35.5 33 5.0 0.014 2.17 1.15, 4.11
Anaemia on admission
None (Hb >11 g⁄dl) 67 3.6 6 9.0 1
Mild (Hb 7.3–10.7 g⁄dl) 1116 60.5 30 2.7 0.004 0.28 0.11, 0.70
Moderate (Hb 5.3–6.7 g⁄dl) 606 32.9 26 4.3 0.089 0.46 0.18, 1.15
Severe (Hb <5.3 g⁄dl) 54 2.9 5 9.3 >0.20 1.04 0.30, 3.62
Concomitant diagnosis
ARI 595 32.0 22 3.7 >0.20 1.02 0.60, 1.70
Malaria 387 20.8 14 3.6 >0.20 0.98 0.54, 1.79
ENT infections 69 3.7 3 4.3 >0.20 1.21 0.37, 3.94
Diarrhoea 65 3.5 6 9.2 0.015 2.84 1.18, 6.84
Pregnancy 10 0.5 2 20.0 0.006 6.75 1.40, 32.53
Hepatopathy 8 0.4 3 37.5 <0.001 16.48 3.81, 71.18
Tuberculosis 7 0.4 3 42.9 <0.001 20.61 4.46, 95.20
Adverse events 119 6.6 15 22.1 <0.001 3.97 2.17, 7.29
P-value based on chi-square tests.
ARI, acute respiratory infections; ENT, ear, nose and throat.
Missing values: spleen size (n = 18), anaemia (n = 15).
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signiﬁcance, but the variable ‘pregnancy’ was kept in the
ﬁnal model because of its clinical meaningfulness. Spleen
size <11 cm and 11–14 cm were merged into a single
category because of similar odd ratios for death. We found
a signiﬁcant interaction between spleen size and sex
(likelihood-ratio test for interaction: P = 0.003) and
therefore stratiﬁed the results. There were no other
signiﬁcant interactions detected in the model. Because of
missing values, the ﬁnal model was based on 1801
observations, representing 97% of the total data.
After adjustment for the other variables in the model,
age <6 years and >15 years remained strongly associated
with death compared with age 6–15 years (OR = 3.90,
95% CI: 1.48–10.27 and OR = 4.01, 95% CI: 1.78–9.03,
respectively) (Table 3). In particular, age >45 years was a
very strong risk factor for death (OR = 38.21, 95% CI:
11.84–123.21). Female sex was a risk factor in patients
with spleen size £14 cm (OR = 3.21, 95% CI: 1.42–7.28),
whereas the association was not found in patients with
spleen size >14 cm. Spleen size >14 cm was identiﬁed as a
risk factor in males (OR = 4.22, 95% CI: 1.95–9.13), but
not in females (OR = 0.64, 95% CI: 0.22–1.84). Con-
comitant tuberculosis (OR = 10.52, 95% CI: 1.61–68.68)
and hepatopathy (OR = 14.87, 95% CI: 2.87–76.92)
remained strongly associated with increased mortality. The
association between pregnancy and death lost its signiﬁ-
cance but a trend towards increased mortality remained
(OR = 5.19, 95% CI: 0.89–30.18). Mild anaemia was a
protective factor compared with the absence of anaemia
(OR = 0.21, 95% CI: 0.07–0.68), whereas moderate to
severe anaemia was not associated with death (OR = 0.40,
95% CI: 0.12–1.30).
Adverse events
Adverse events were strongly associated with mortality
(OR = 4.84, 95% CI: 2.41–9.70). After stratiﬁcation of
data by the type of drug, adverse events recorded in
patients treated with Glucantime  (OR = 5.28, 95% CI:
Table 3 Multivariate analysis of risk factors for in-hospital death among 1801 primary VL cases at Amudat hospital, Uganda
Total
(n = 1801) Deaths (n = 59) CFR
Adjusted
OR 95% CI of OR P-value n % n %
Age
0–5 years 327 18.2 12 3.7 3.90 1.48, 10.27 0.006
6–15 years 807 44.8 8 1.0 1
16– years 637 35.4 30 4.7 4.01 1.78, 9.03 0.001
over 45 years 30 1.7 9 30.0 38.21 11.84, 123.21 <0.001
Sex
Spleen size £14 cm
Males 797 68.4 13 1.6 1
Females 368 31.6 16 4.3 3.21 1.42, 7.28 0.005
Spleen size >14 cm
Males 459 72.2 23 5.0 1
Females 177 27.8 7 3.9 0.49 0.18, 1.33 0.160
Spleen size on admission
Males
£14 cm 797 63.5 13 1.6 1
>14 cm 459 36.5 23 5.0 4.22 1.95, 9.13 <0.001
Females
£14 cm 368 67.5 16 4.3 1
>14 cm 177 32.5 7 3.9 0.64 0.22, 1.84 >0.20
Anaemia
None (Hb >11 g⁄dl) 60 3.3 4 6.7 1
Mild (Hb 7.3–10.7 g⁄dl) 1097 60.9 28 2.5 0.21 0.07, 0.68 0.009
Moderate to severe (Hb 0–6.7 g⁄dl) 644 35.8 27 4.2 0.40 0.12, 1.30 0.127
Concomitant diagnosis
Hepatopathy 8 0.4 3 37.5 14.87 2.87, 76.92 0.001
TB 7 0.4 3 42.9 10.52 1.61, 68.68 0.014
Pregnancy 9 0.5 2 22.2 5.19 0.89, 30.18 0.067
Adverse events 132 7.3 14 10.6 4.84 2.41, 9.70 <0.001
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11.29) were associated with death, but no association was
found in patients treated with ampB deoxycholate. The
adverse events recorded for the patients who died while on
Glucantime  (n = 5) were: epigastric pain (n = 1), acute
pancreatitis (n = 1), disrhythmia (n = 1), cardiac failure
(n = 1), and sudden death (n = 1), whereas those recorded
for the patients who died while on Pentostam  (n = 10)
were vomiting (n = 6), anorexia (n = 2) and respiratory
failure (n = 2).
Discussion
The overall mortality rate among 1858 primary VL
patients admitted between 2000 and 2005 at Amudat
Hospital, eastern Uganda was 3.7%. Several risk factors
for in-hospital death were identiﬁed: age <6 and >15 years
(in particular >45 years), female sex in patients with spleen
sizes <14 cm, spleen size >14 cm in males, concomitant
tuberculosis or liver disease, and occurrence of adverse
events during treatment. We do not have an explanation
for the observed interaction between sex and spleen size,
which may be related to another, unmeasured variable.
Young children (<5–6 years) and adults >45 years are at
greater risk of death when treated with SbV in Ethiopia
and Sudan (Seaman et al. 1996; Lyons et al. 2003; Collin
et al. 2004). We found a strikingly high (29%) case-fatality
rate among >45-year-old patients in Uganda, which is
consistent with previous ﬁndings in Ethiopia (36%) and
Sudan (26–28%) (Seaman et al. 1996; Lyons et al. 2003;
Collin et al. 2004). The reason for the high mortality in
this age group is not known but an increased prevalence of
co-morbidities, a weakened immune system and⁄or a
greater susceptibility to severe adverse events with SbV
may be causal factors.
Chronic liver disease or tuberculosis was associated with
rising mortality. This is likely to be caused by a direct
synergistic impact of these conditions on the general
condition of the patients, delayed diagnosis due to similar
clinical presentation (e.g. VL and miliary tuberculosis),
increased toxicity of anti-leishmanial drugs, or a combi-
nation of these factors. Tuberculosis may be an indicator of
concomitant HIV infection, which is strongly associated
with fatal outcome in patients treated with SbV in East
Africa (Ritmeijer et al. 2001, 2006; Lyons et al. 2003).
Both SbV and ampB deoxycholate are more toxic and less
efﬁcient in HIV–VL co-infected patients. HIV testing was
not done routinely at Amudat Hospital. The lack of this
potential essential prognostic determinant is unlikely to
have had a signiﬁcant impact on our analysis. Indeed, low
(1.4%) HIV seroprevalence was found among 206 con-
secutive VL patients during an unlinked anonymous testing
conducted at Amudat hospital in 2002 and 2003
(F. Chappuis, personal communication).
In contrast with previous studies in Ethiopia and Sudan,
we did not ﬁnd severe anaemia or malnutrition to be
associated with increased mortality (Seaman et al. 1996;
Lyons et al. 2003; Collin et al. 2004). The odds ratio for
death in patients with different degrees of anaemia was
compared with patients with no anaemia. The absence of
apparent anaemia cannot always be considered as a sign of
well-being, as it can be due to moderate or severe dehydra-
tion (haemoconcentration). This may explain why mild
anaemia was associated with a better outcome in our study.
Adverse effects during treatment with Pentostam  or
Glucantime , but not with ampB deoxycholate, were
associated with higher mortality. Pentavalent antimonials
have a high potential of toxicity in VL patients. They
should be promptly interrupted in presence of ominous
adverse effects consistent with acute clinical pancreatitis
(e.g. epigastric pain not responding to antacids) or
disrhythmias (e.g. palpitations), which usually cannot be
investigated in rural areas of East Africa. It should be
emphasized that some life-threatening adverse effects
caused by ampB deoxycholate, such as hypokalemia and
acute renal failure, are likely to have been overlooked as
they are difﬁcult to diagnose clinically, and as blood
potassium and creatinine were not monitored during
treatment. This statement is supported by the similar case-
fatality rates found in patients treated with ampB deoxy-
cholate or SbV at Amudat Hospital, Uganda, as was
previously reported (Mueller et al. 2008).
We found a trend towards a higher case-fatality rate
among pregnant women. Two of the nine patients died, one
treated with SbV and one treated with ampB deoxycholate.
The low number of patients precludes any conclusion but
a recent report from Sudan highlights the toxicity of SbV on
the foetus, as 13 of 39 pregnant VL patients treated with
SbV suffered abortions (compared with none in patients
treated with Ambisome) (Mueller et al. 2006). Women of
childbearing age should undergo a pregnancy test to avoid
the administration of SbV in this population.
Distance to the health centre was not associated with a
higher mortality in the multivariate analysis. Nevertheless,
it is striking that 70% of the patients were from Kenya,
sometimes traveling large distances. This fact motivated
MSF in 2006 to transfer the VL management and
treatment centre to Kacheliba hospital, which is located on
the Kenyan part of the Pokot VL focus.
The main limitations of this study are related to data
quality and change in diagnostic algorithm over time.
Spleen size measurement was not sufﬁciently standardized,
which may have resulted in variable techniques of
measuring among the different physicians. Haemoglobin
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interpretation (Lovibond method). The diagnostic algo-
rithm changed twice during the data collection. Although
both the DAT and the rK39 dipsticks were locally
validated against the previous test in use (spleen aspiration
and DAT, respectively), we cannot exclude a slight shift in
the population of conﬁrmed VL cases over time. Final
outcome of VL treatment is traditionally assessed at
6 months after treatment. Active follow-up, however, was
not possible in our setting because of logistic constraints.
Our study refers only to in-hospital mortality, and this
should be taken into account when comparing these results
with other reports.
Our study provides further evidence that there is an
urgent need for new VL drugs in East Africa. Miltefosine
was effective in HIV-negative Ethiopian VL patients and
markedly safer than sodium stibogluconate in HIV co-
infected patients (Ritmeijer et al. 2006). Despite its tera-
togenicity, miltefosine should be further evaluated in East
Africa, preferably in combination with another anti-leish-
manial drug. Indeed, most VL experts agree that drug
combinations are the way to go (Bryceson 2001). Paro-
momycin combined with sodium stibogluconate is cur-
rently being re-evaluated in several East African countries.
Moreover, the Drugs for Neglected Diseases initiative will
sponsor studies on Ambisome-based combinations in this
region. While new treatments are likely to replace SbV
mono-therapy in the future, the treatment approach for
patients at high risk of death with SbV must change now.
Ambisome is very effective and safe for the treatment of
VL, and is being used as ﬁrst-line treatment in developed
countries (Bern et al. 2006). A recent agreement between
the WHO and Gilead Pharma led to a drastic price
reduction (20 US$ per 50 mg vial) for non-proﬁt groups
treating VL patients in developing countries. Despite the
fact that Ambisome remains more expensive than SbV, it
should be used in VL patients over 45 years of age, with
severe co-morbidities (e.g. HIV infection, tuberculosis,
liver disease), during pregnancy, or in patients presenting
ominous adverse effects during SbV treatment.
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